Genzyme Corporation and SangStat Medical Corporation have reached an agreement under which Genzyme will acquire SangStat in an all cash transaction valued at $22.50 per outstanding share, or approximately $600 million. Genzyme expects to complete the acquisition in early September. The transaction is expected to be dilutive to Genzyme’s GAAP earnings due to amortization through Read more about Genzyme To Acquire SangStat Medical Corporation[…]